Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

Protein kinase C (PKC), a family of phospholipid-dependent serine/threonine kinase, is classed into three subfamilies based on their structural and activation characteristics: conventional or classic PKC isozymes (cPKCs; α, βI, βII, and γ), novel or non-classic PKC isozymes (nPKCs; δ, ε, η, and θ),...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, Jeong-Hun Kang
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	protein kinase C cancer inhibitor activator signaling pathway clinical trial Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/f14f609da4c24b3a97c0233460bc6c6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f14f609da4c24b3a97c0233460bc6c6b
record_format	dspace
spelling	oai:doaj.org-article:f14f609da4c24b3a97c0233460bc6c6b2021-11-25T18:40:20ZActivators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials10.3390/pharmaceutics131117481999-4923https://doaj.org/article/f14f609da4c24b3a97c0233460bc6c6b2021-10-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1748https://doaj.org/toc/1999-4923Protein kinase C (PKC), a family of phospholipid-dependent serine/threonine kinase, is classed into three subfamilies based on their structural and activation characteristics: conventional or classic PKC isozymes (cPKCs; α, βI, βII, and γ), novel or non-classic PKC isozymes (nPKCs; δ, ε, η, and θ), and atypical PKC isozymes (aPKCs; ζ, ι, and λ). PKC inhibitors and activators are used to understand PKC-mediated intracellular signaling pathways and for the diagnosis and treatment of various PKC-associated diseases, such as cancers, neurological diseases, cardiovascular diseases, and infections. Many clinical trials of PKC inhibitors in cancers showed no significant clinical benefits, meaning that there is a limitation to design a cancer therapeutic strategy targeting PKC alone. This review will focus on the activators and inhibitors of PKC and their applications in clinical trials.Takahito KawanoJunichi InokuchiMasatoshi EtoMasaharu MurataJeong-Hun KangMDPI AGarticleprotein kinase Ccancerinhibitoractivatorsignaling pathwayclinical trialPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1748, p 1748 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	protein kinase C cancer inhibitor activator signaling pathway clinical trial Pharmacy and materia medica RS1-441
spellingShingle	protein kinase C cancer inhibitor activator signaling pathway clinical trial Pharmacy and materia medica RS1-441 Takahito Kawano Junichi Inokuchi Masatoshi Eto Masaharu Murata Jeong-Hun Kang Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
description	Protein kinase C (PKC), a family of phospholipid-dependent serine/threonine kinase, is classed into three subfamilies based on their structural and activation characteristics: conventional or classic PKC isozymes (cPKCs; α, βI, βII, and γ), novel or non-classic PKC isozymes (nPKCs; δ, ε, η, and θ), and atypical PKC isozymes (aPKCs; ζ, ι, and λ). PKC inhibitors and activators are used to understand PKC-mediated intracellular signaling pathways and for the diagnosis and treatment of various PKC-associated diseases, such as cancers, neurological diseases, cardiovascular diseases, and infections. Many clinical trials of PKC inhibitors in cancers showed no significant clinical benefits, meaning that there is a limitation to design a cancer therapeutic strategy targeting PKC alone. This review will focus on the activators and inhibitors of PKC and their applications in clinical trials.
format	article
author	Takahito Kawano Junichi Inokuchi Masatoshi Eto Masaharu Murata Jeong-Hun Kang
author_facet	Takahito Kawano Junichi Inokuchi Masatoshi Eto Masaharu Murata Jeong-Hun Kang
author_sort	Takahito Kawano
title	Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
title_short	Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
title_full	Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
title_fullStr	Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
title_full_unstemmed	Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
title_sort	activators and inhibitors of protein kinase c (pkc): their applications in clinical trials
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f14f609da4c24b3a97c0233460bc6c6b
work_keys_str_mv	AT takahitokawano activatorsandinhibitorsofproteinkinasecpkctheirapplicationsinclinicaltrials AT junichiinokuchi activatorsandinhibitorsofproteinkinasecpkctheirapplicationsinclinicaltrials AT masatoshieto activatorsandinhibitorsofproteinkinasecpkctheirapplicationsinclinicaltrials AT masaharumurata activatorsandinhibitorsofproteinkinasecpkctheirapplicationsinclinicaltrials AT jeonghunkang activatorsandinhibitorsofproteinkinasecpkctheirapplicationsinclinicaltrials
_version_	1718410869929410560

Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

Ejemplares similares